# Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy

> **NCT07743541** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Gilead Sciences** · enrollment: 100 (estimated)

## Conditions studied

- Uterine Endometrial Cancer

## Interventions

- **DRUG:** TUB-040 - Dose escalation
- **DRUG:** TUB-040 - RP2D

## Key facts

- **NCT ID:** NCT07743541
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2029-09
- **Final completion:** 2029-09
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07743541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07743541, "Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07743541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*